Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05065567 · ClinicalTrials.gov registry record · Phase 3
Haloperidol, Droperidol, Ondansetron in Cannabis Hyperemesis
A Phase 3 study, sponsored by Corewell Health South.
- Terminated
- Registry status
- Phase 3
- Development phase
- 32
- Enrollment target
NCT05065567 is a Phase 3 study that was terminated before completion, run by Corewell Health South. The registered enrollment target is 32 participants.
The verdict
NCT05065567, a Phase 3 study, was terminated before completion, sponsored by Corewell Health South.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to compare two commonly used agents for the treatment of cyclic vomiting to see if one agent is inferior to the other in time to improvement in symptoms, need for repeat or rescue medications, treatment failures and complications/side effects.
Interventions
- DRUG Haloperidol
- DRUG Ondansetron 8mg
- DRUG Droperidol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2021-08-30 |
| Est. Completion | 2023-11-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05065567
The ClinicalTrials.gov registry entry for NCT05065567 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corewell Health South, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Haloperidol is the first listed.
NCT05065567 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05065567 about?
NCT05065567 is a clinical study titled "Haloperidol, Droperidol, Ondansetron in Cannabis Hyperemesis". The purpose of this study is to compare two commonly used agents for the treatment of cyclic vomiting to see if one agent is inferior to the other in time to improvement in symptoms, need for repeat or rescue medications, treatment failures and complications/side effects.
What is the current status of trial NCT05065567?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 32 participants. The study started on 2021-08-30. Estimated completion is 2023-11-20.
What interventions are being tested in trial NCT05065567?
The interventions under investigation include: Haloperidol (DRUG), Ondansetron 8mg (DRUG), Droperidol (DRUG).
Who is sponsoring clinical trial NCT05065567?
This trial is sponsored by Corewell Health South, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.